<DOC>
	<DOC>NCT00643968</DOC>
	<brief_summary>Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (&lt; 50 copies/mL) (c/mL) at 48 weeks (W48) Main Secondary objectives: Comparison of the two arms for genotypic resistance profile in case of virological failure CD4 changes from baseline Evolution of the lipid profile and morphological changes in fat distribution, and safety Efficacy and genotypic profile data, results of lipid markers, morphological changes and main biological parameters</brief_summary>
	<brief_title>Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Stable HAART ≥ 3 months HIV1 RNA &lt; 50 c/mL ≥ 6 months No HAART failure history Weight &gt; 45 kg No CD4+ cell count criteria No significant laboratory or clinical abnormalities Creatinine Clearance &gt; 60 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>HIV virological control</keyword>
	<keyword>Lipid profile and morphological fat distribution</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>